Amgen (AMGN) Research Report — Score, Intrinsic Value, Peer Rankings

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

$414.61 $8.57(2.11%)as of Friday's close

52‑wk Range

$269.77

$447.03

Cap ($M USD) $224,151

P/E 25.8

EPS (1Y)31.8%

Dividend$10.08

Last Filing06/30/26

Sales ($M)38,095

Fwd. P/E 17.0

Sales (1Y)9.1%

Fwd. Yield 2.4%

Next Earnings11/03/26

AMGN has outperformed the S&P 500 by 34.7% in the past year.

AMGN has outperformed its sector by 25.0% in the past year.

The Healthcare sector has outperformed the market by 9.7% in the past year.

ANALYST CONSENSUS

Buy

The consensus rating has worsened a little since last month when it was also Buy.

Strong Buy

Buy

Hold

Sell

Strong Sell

Strong BuyBuyHoldSellStrong Sell

QUANTITATIVE SCORES

Fair Value

$374.98

Margin of Safety

-10%

The Margin of Safety is the difference between a company's Fair Value and the current price. See more on page 8.

1 warning

Details on Page 8

Value Score

Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks

Quality Score

Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics.

Growth Score

Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks.

Sentiment Score

Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals.

BUSINESS SUMMARY

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees 31,500Homepage www.amgen.comHeadquarters Thousand Oaks, CA

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

VALUATION SUMMARY

	AMGN	Industry	S&P 500
Value Score	72	71	69
Price / Earnings	25.8	30.7	27.0
Price / Sales	5.9	4.9	3.7
Price / Free Cash Flow	22.2	24.9	36.3
Price / Book	19.2	7.0	5.9
Price / Tangible Book	-	-	374.0
EV / EBITDA	15.2	22.1	19.7
EPS Predict. Pctl.	81	72	71
Piotroski F Score	8	8	6

5‑Year P/E Range	14.9 56.4
5‑Year P/B Range	13.1 147.6
5‑Year P/S Range	4.2 6.5

GROWTH SUMMARY

	AMGN	Industry	S&P 500
Growth Score	86	70	78
Sales Growth
Sales Growth Next Year	3.5%	9.4%	23.2%
Sales 1‑Year Chg (%)	9.1%	16.7%	22.6%
Sales 3‑Year Avg (%)	12.7%	14.8%	14.8%
Sales 5‑Year Avg (%)	8.4%	9.8%	13.4%
EPS Growth
Next Yr. Growth Est.	6.0%	26.0%	33.7%
EPS 1‑Year Chg (%)	31.8%	51.1%	37.3%
EPS 3‑Year Avg (%)	2.7%	29.8%	18.3%
EPS 5‑Year Avg (%)	10.3%	22.5%	15.3%

PEERS ANALYSIS SUMMARY

Ticker

Cell value has been edited

Company

Cell value has been edited

Cap ($M USD)

Cell value has been edited

P/E

Cell value has been edited

Fwd. Yield

Cell value has been edited

1M Return

Cell value has been edited

1Y Return

Cell value has been edited

Margin of Safety

Cell value has been edited

Value Score

Cell value has been edited

Growth Score

Cell value has been edited

Quality Score

Cell value has been edited

MRK

Merck & Co

$367,065

118.1

2.3%

-4.3%

97.4%

-5%

NVS

Novartis

$276,477

22.0

3.3%

-9.1%

22.6%

AZN

AstraZeneca

$258,348

24.9

1.9%

-1.8%

13.2%

AMGN

Amgen

$224,151

25.8

2.4%

-6.2%

57.1%

-10%

GILD

Gilead Sciences

$187,146

2.2%

2.0%

39.3%

-19%

NVO

Novo Nordisk

$171,371

9.5

4.6%

-20.3%

-27.4%

PFE

Pfizer

$163,409

37.7

6.0%

0.4%

30.0%

17%

BMY

Bristol-Myers Squibb

$128,405

13.9

4.0%

-7.4%

51.8%

26%

GSK

$98,652

15.5

3.7%

-5.4%

29.0%

32%

SNY

Sanofi

$98,505

21.7

5.9%

-10.7%

-3.7%

30%

BIIB

Biogen

$33,628

40.4

3.1%

67.8%

11%

GRFS

Grifols

$5,002

9.5

1.4%

-9.1%

-23.5%

39%

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

PROFITABILITY SUMMARY

	AMGN	Industry	S&P 500
Quality Score	88	79	75
Gross Margin	69.5%	72.9%	32.8%
Operating Margin	30.0%	27.8%	16.9%
Net Margin	23.0%	15.9%	13.8%
Return on Assets	9.6%	10.6%	15.4%
Return on Equity	74.8%	35.4%	40.2%
ROIC	16.9%	18.9%	32.2%

RETURNS SUMMARY

	AMGN	Industry	S&P 500
Sentiment Score	98	59	62
5‑Day Return	7.5%	1.8%	1.2%
1‑Month Return	-6.2%	-3.6%	1.1%
YTD Return	29.3%	14.5%	14.0%
1‑Year Return	57.1%	39.2%	18.5%
3‑Year Return	70.0%	54.2%	85.1%
5‑Year Return	126.8%	74.8%	85.9%
Beta 1‑Year	0.53	0.17	1.00

DIVIDEND

	AMGN	Industry
Forward Dividend Yield	2.4%	2.2%
Payout Ratio	60.4%	44.3%
TTM Yield	2.4%	-
Fwd. Div. Per Share	$10.08	$4.38
Div. 1Y Chg (%)	5.9%	-
Div. 3Y Avg (%)	5.8%	-
Div. 5Y Avg (%)	7.4%	-
Cons. Growth Years	10+	-
Div. Coverage Ratio	1.6	1.5

DEBT & EQUITY

Current Ratio	1.4
Quick Ratio	1.1
Price	$414.61
Net Cash Per Share	-$80.58
Equity Per Share	$21.62
Debt / Equity	4.9
Solvency Ratio	17%
Interest Coverage	4.9
Short % of Float	2.4%
Altman Z‑Score	2.2

ANALYST REVISIONS

Current Quarter EPS
# Up Last 30 days	13.00
# Down Last 30 days	10.00
Mean Estimate	5.78
% Change (30 Days)	-

Next Quarter EPS
# Up Last 30 days	11.00
# Down Last 30 days	12.00
Mean Estimate	5.80
% Change (30 Days)	-

MEAN ESTIMATE TREND

	Cur Qtr	Next Qtr	Cur Year	Next Year
Latest	$5.78	$5.80	$23.06	$24.45
30 Days Ago	$5.78	$5.80	$23.04	$24.40
90 Days Ago	$5.75	$5.86	$22.39	$23.48
% Change (90 Days)	0.5%	-1.0%	3.0%	4.1%

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

EARNINGS SURPRISES

Earnings surprise is the difference between a company's announced earnings and the average analyst estimated value. Surprises typically causes the stock price to jump and are often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)

Surprise Type	Amount	Percent
Positive Quarters (> 2%)	10	83.3%
Negative Quarters (< 2%)	0	-
In-Line Quarters (within 2%)	2	16.7%

Surprise Detail (Last 6 Quarters)

Surprise Type	Announce Date	Period End Date	Actual EPS	Est. EPS	Surprise (%)
Positive	08/04/26	06/30/26	$6.29	$5.60	12.3%
Positive	04/30/26	03/31/26	$5.15	$4.73	8.9%
Positive	02/03/26	12/31/25	$5.29	$4.76	11.1%
Positive	10/29/25	09/30/25	$5.64	$5.00	12.8%
Positive	08/05/25	06/30/25	$6.02	$5.26	14.4%
Positive	05/01/25	-	$4.90	$4.16	17.8%

RISK

	AMGN	Industry	S&P 500
Best Monthly Return (5Y)	17.3%	12.9%	9.6%
Worst Monthly Return (5Y)	-15.6%	-6.8%	-9.6%
Beta 1‑Year	0.53	0.17	1.00
Volatility 1‑Year	0.29	0.17	0.13
Volatility 1Y Pctl.	28	-	-
Max Drawdown 1‑Year	-16.6%	-19.5%	-8.8%
Max Drawdown 3‑Year	-22.7%	-27.6%	-18.7%
Max Drawdown 5‑Year	-24.9%	-30.5%	-24.6%

SEASONALITY

Seasonal Performance vs the S&P 500

5-YEAR RELATIVE PERFORMANCE VS S&P 500

Relative to the S&P 500 baseline, AMGN has outperformed the S&P 500 by 39.1% in the past 5 Years.

AMGN has outperformed its sector by 91.9% in the past 5 Years.

The Healthcare sector has underperformed the market by -52.8% in the past 5 Years.

Amgen 5-YEAR RELATIVE PERFORMANCE VS S&P 500 chart

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

Overall Rating
vs. Peers

Ratings scores are relative to industry groups. They compare key metrics to rank stocks vs. their competitors.
For example, higher growth than peers will score high even when the absolute growth is below the market average.

Growth vs Peers

Ticker

Cell value has been edited

Company

Cell value has been edited

Growth Rating vs. Peers

Cell value has been edited

Sales QoQ Chg.

Cell value has been edited

Eps QoQ Chg.

Cell value has been edited

Sales Growth Next Y.

Cell value has been edited

Sales 1Y Chg (%)

Cell value has been edited

Sales 3Y Avg (%)

Cell value has been edited

Sales 5Y Avg (%)

Cell value has been edited

AZN

AstraZeneca

6.4%

2.6%

6.1%

8.6%

11.3%

15.7%

NVO

Novo Nordisk

2.1%

-20.5%

1.3%

5.6%

17.8%

20.4%

AMGN

Amgen

9.5%

64.9%

3.5%

9.1%

12.7%

8.4%

GILD

Gilead Sciences

10.2%

6.4%

5.5%

3.6%

2.7%

PFE

Pfizer

2.6%

-4.0%

-0.2%

-7.0%

2.9%

Valuation vs Peers

Ticker

Cell value has been edited

Company

Cell value has been edited

Valuation Rating vs. Peers

Cell value has been edited

P/E

Cell value has been edited

Fwd. P/E

Cell value has been edited

PEG Trailing

Cell value has been edited

P/S

Cell value has been edited

P/B

Cell value has been edited

5Y P/E Range

Cell value has been edited

NVO

Novo Nordisk

9.5

1.8

0.4

3.4

5.1

9.3

56.8

AZN

AstraZeneca

24.9

14.4

1.4

4.2

5.1

23.3

AMGN

Amgen

25.8

17.0

2.5

5.9

19.2

14.9

56.4

PFE

Pfizer

37.7

9.9

2.6

1.9

6.3

GILD

Gilead Sciences

15.3

6.2

15.8

9.9

Efficiency vs Peers

Ticker

Cell value has been edited

Company

Cell value has been edited

Efficiency Rating vs. Peers

Cell value has been edited

Gross Margin

Cell value has been edited

Operating Margin

Cell value has been edited

Net Margin

Cell value has been edited

5Y ROE Range

Cell value has been edited

5Y ROA Range

Cell value has been edited

NVO

Novo Nordisk

80.7%

43.1%

35.4%

52.6%

90.3%

20.6%

30.9%

AMGN

Amgen

69.5%

30.0%

23.0%

52.8%

624.8%

3.4%

11.8%

AZN

AstraZeneca

81.9%

22.8%

17.0%

-3.5%

21.9%

-1.3%

9.3%

PFE

Pfizer

73.2%

26.7%

6.8%

-3.0%

33.6%

-1.2%

16.5%

GILD

Gilead Sciences

79.6%

38.5%

-10.6%

-27.4%

39.2%

-5.8%

16.1%

Financial Strength vs Peers

Ticker

Cell value has been edited

Company

Cell value has been edited

Financial Str. Rating vs. Peers

Cell value has been edited

Debt / Equity

Cell value has been edited

Interest Coverage

Cell value has been edited

Quick Ratio

Cell value has been edited

Intangibles %

Cell value has been edited

Solvency Ratio

Cell value has been edited

Short % of Float

Cell value has been edited

AZN

AstraZeneca

0.6

8.2

0.7

50.9%

29%

0.2%

NVO

Novo Nordisk

0.6

30.8

0.5

20.5%

38%

1.0%

PFE

Pfizer

0.7

2.6

1.0

58.9%

12%

2.7%

AMGN

Amgen

4.9

1.1

40.9%

17%

2.4%

GILD

Gilead Sciences

2.2

-1.0

1.1

45.3%

-1%

1.9%

Dividends vs Peers

Ticker

Cell value has been edited

Company

Cell value has been edited

Dividends Rating vs. Peers

Cell value has been edited

Fwd. Yield

Cell value has been edited

TTM Yield

Cell value has been edited

Price

Cell value has been edited

Fwd. Div. Per Share

Cell value has been edited

Consecutive Div. Growth Years

Cell value has been edited

Payout Ratio

Cell value has been edited

NVO

Novo Nordisk

4.6%

$38.80

$1.80

14.3%

PFE

Pfizer

6.0%

$28.67

$1.72

10+

226.3%

AMGN

Amgen

2.4%

$414.61

$10.08

10+

60.4%

AZN

AstraZeneca

1.9%

$166.58

$3.20

46.5%

GILD

Gilead Sciences

2.2%

$150.93

$3.28

10+

Momentum vs Peers

Ticker

Cell value has been edited

Company

Cell value has been edited

Momentum Rating vs. Peers

Cell value has been edited

1M Return

Cell value has been edited

3M Return

Cell value has been edited

6M Return

Cell value has been edited

YTD Return

Cell value has been edited

1Y Return

Cell value has been edited

Beta 1Y

Cell value has been edited

Volatility 1Y

Cell value has been edited

Price vs 52‑wk High (%)

Cell value has been edited

GILD

Gilead Sciences

2.0%

22.6%

10.5%

25.2%

39.3%

0.34

0.26

96.0%

PFE

Pfizer

0.4%

23.2%

8.7%

21.1%

30.0%

0.33

0.23

98.2%

AMGN

Amgen

-6.2%

18.2%

18.7%

29.3%

57.1%

0.53

0.29

92.8%

AZN

AstraZeneca

-1.8%

-9.7%

-10.4%

-3.4%

13.2%

0.23

0.30

78.3%

NVO

Novo Nordisk

-20.3%

-17.5%

11.9%

-20.1%

-27.4%

1.04

0.46

60.5%

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

DIVIDEND DETAIL

CALENDAR YEAR DIVIDEND HISTORY

Year

Cell value has been edited

Ex-Dividend Date

Cell value has been edited

Pay Date

Cell value has been edited

Text

Cell value has been edited

Amount

Cell value has been edited

2026 Dividends

$7.56

08/21/26

09/11/26

Regular

$2.52

05/15/26

06/05/26

Regular

$2.52

02/13/26

03/06/26

Regular

$2.52

2025 Dividends

$9.52

11/21/25

12/12/25

Regular

$2.38

08/22/25

09/12/25

Regular

$2.38

05/16/25

06/06/25

Regular

$2.38

02/14/25

03/07/25

Regular

$2.38

2024 Dividends

$9.00

11/18/24

12/09/24

Regular

$2.25

08/16/24

09/06/24

Regular

$2.25

05/16/24

06/07/24

Regular

$2.25

02/15/24

03/07/24

Regular

$2.25

2023 Dividends

$8.52

11/16/23

12/08/23

Regular

$2.13

08/17/23

09/08/23

Regular

$2.13

05/17/23

06/08/23

Regular

$2.13

02/14/23

03/08/23

Regular

$2.13

2022 Dividends

$7.76

11/16/22

12/08/22

Regular

$1.94

08/17/22

09/08/22

Regular

$1.94

05/16/22

06/08/22

Regular

$1.94

02/14/22

03/08/22

Regular

$1.94

UPCOMING DIVIDEND

Cell value has been edited

Ex-Dividend Date

08/21/26

Payment Date

09/11/26

Amount

$2.52

Type

Regular

DIVIDEND RATE

Cell value has been edited

Regular Dividend

$2.52

Forward Dividend Rate

$10.08

Forward Dividend Yield

2.4%

Trailing 12 Months Dividends

$9.94

Trailing 12 Months Yield

2.4%

STATISTICS

Cell value has been edited

Payout Ratio

60.4

Dividend Coverage Ratio

1.6

Consecutive Growth Years

10+

3 Year Growth Rate

5.8%

5 Year Growth Rate

7.4%

10 Year Growth Rate

9.7%

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

FINANCIAL STATEMENT SUMMARY

Income Statement

Revenue

Operating Income

Net income

Earnings per share diluted

Average shares diluted

P/E Ratio

Balance Sheet

Cash

Current assets

Net Property, Plant and Equipment

Working Capital

Net Debt

Stockholders' Equity

Cash Flow

Operating Cash Flow

Cap Ex

Free Cash Flow

Free Cash Flow per share

Profitability

Operating Margin

Return on Assets

Return on Equity

Return on Invested Capital

Dividends

Dividends Per Share

Dividend Yield

Dividend Growth

Dividend Coverage

25,979

26,323

28,190

33,424

36,751

38,095

8.4%

7,639

9,566

7,897

7,258

9,080

11,426

8.9%

5,893

6,552

6,717

4,090

7,711

8,743

8.7%

$10.28

$12.11

$12.49

$7.56

$14.23

$16.10

9.9%

573

541

538

541

542

544

-1.1%

23.2

21.1

20.5

33.3

25.3

25.8

2.2%

8,037

9,305

10,944

11,973

9,129

13,989

12.4%

19,385

22,186

30,332

29,030

29,057

34,961

13.3%

5,184

5,427

5,941

6,543

7,913

8,547

11.1%

7,201

6,499

11,940

5,931

3,568

9,459

5.9%

25,272

29,640

53,669

48,126

45,475

43,315

12.1%

6,700

3,661

6,232

5,877

8,658

11,688

12.5%

9,261

9,721

8,471

11,490

9,958

12,478

6.5%

-880

-936

-1,112

-1,096

-1,858

-2,303

8,381

8,785

7,359

10,394

8,100

10,175

4.2%

$14.63

$16.24

$13.68

$19.21

$14.94

$18.72

5.4%

29.4%

36.3%

28.0%

21.7%

24.7%

30.0%

0.4%

9.5%

10.6%

7.8%

4.4%

8.6%

9.6%

0.2%

88.0%

179.0%

107.8%

69.6%

89.1%

74.8%

-3.4%

16.4%

19.4%

14.5%

10.1%

15.7%

16.9%

0.5%

$7.04

$7.76

$8.52

$9.00

$9.52

$10.08

7.9%

3.4%

3.2%

3.1%

3.7%

2.9%

2.4%

-7.1%

10.2%

9.8%

5.6%

5.8%

8.9%

1.5x

1.6x

1.5x

0.8x

1.5x

1.7x

2.6%

USD in Millions

Cell value has been edited

Chart

Cell value has been edited

2021

Cell value has been edited

2022

Cell value has been edited

2023

Cell value has been edited

2024

Cell value has been edited

2025

Cell value has been edited

TTM

Cell value has been edited

CAGR

Cell value has been edited

VALUATION & PROFITABILITY HISTORY

Date

Cell value has been edited

TTM

Cell value has been edited

1 Yr Ago

Cell value has been edited

2 Yrs. Ago

Cell value has been edited

3 Yrs. Ago

Cell value has been edited

4 Yrs. Ago

Cell value has been edited

Price / Earnings

25.8

24.7

44.6

18.1

22.4

Price / Cash Flow

18.1

12.2

26.2

13.3

13.5

Price / Book

19.2

23.5

33.4

26.7

132.4

Price / Tangible Book

Price / Sales

5.9

4.3

5.7

5.5

4.9

EV / EBITDA

15.2

12.2

18.8

11.7

12.5

Forward Dividend Yield

2.4%

3.5%

2.9%

3.2%

3.4%

Shareholder Yield

2.4%

3.5%

2.9%

3.2%

10.7%

Gross Margin

69.5%

64.5%

63.3%

74.2%

75.8%

Net Margin

23.0%

19.0%

10.1%

30.0%

24.9%

Return on Assets

9.6%

7.3%

3.4%

10.9%

10.8%

Return on Equity

74.8%

89.1%

52.8%

117.7%

271.9%

ROIC

16.9%

14.0%

8.7%

18.9%

Amgen (AMGN)Healthcare / Drug Manufacturers - General

StockRover

Stock Report | September 27, 2026

WARNINGS

Name

Cell value has been edited

Severity

Cell value has been edited

Details

Cell value has been edited

GAAP Earnings vs. Pro Forma

Low

Official EPS: $4.37; Announced EPS: $6.29

The GAAP compliant earnings that the company filed with the SEC are less than the pro-forma earnings they announced to the press. Pro-forma earnings can exclude special one-time charges but some distressed companies post these "one-time" charges quarter after quarter.

REPORT TIPS

Metric Definitions

Metric descriptions are available at
stockrover.com/help/metrics/metric-overview

Quantitative Scores

Our scores analytics is to offer our concise analysis of a stock in powerful, but easy to digest format. Each of the composite score metrics are designed to use the best available accounting practices as well as source data from SEC filings. The scores are computed for a company vs. the market as a whole.

Fair Value

Fair value performs a forecasted discounted cash flow analysis of a company to determine the company's intrinsic value based on the expected future cash flows the company will produce. It basically determines what a company is worth based on how much cash flow it is expected to generate for you in the future, taking into account the time value of money and the predictability of those forecasted cash flows.

Peers

Peer ratings are computed from ranking companies in the same industry group. The selection of peers shown in the tables above are chosen from the same industry and closest proximity of revenue.

DISCLAIMER

Financial Statements and Historical Prices Provided by Morningstar. © 2026 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Stock Rover and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely.

The information provided does not constitute investment advice, nor does it constitute a recommendation to buy or sell any security. Stock Rover LLC and its content providers are not responsible for any losses resulting from trading decisions arising from any use of this information. Past performance is no guarantee of future results.

The information provided is as of the date written and is subject to change without notice

Additional data provided by Zacks, Intrinio, Quandl, Yodlee, IEX Cloud

Amgen (AMGN) Research Report — September 27, 2026

ANALYST CONSENSUS

QUANTITATIVE SCORES

BUSINESS SUMMARY

VALUATION SUMMARY

GROWTH SUMMARY

PEERS ANALYSIS SUMMARY

PROFITABILITY SUMMARY

RETURNS SUMMARY

DIVIDEND

DEBT & EQUITY

ANALYST REVISIONS

MEAN ESTIMATE TREND

EARNINGS SURPRISES

RISK

SEASONALITY

5-YEAR RELATIVE PERFORMANCE VS S&P 500

Growth vs Peers

Valuation vs Peers

Efficiency vs Peers

Financial Strength vs Peers

Dividends vs Peers

Momentum vs Peers

DIVIDEND DETAIL

Returns

CALENDAR YEAR DIVIDEND HISTORY

UPCOMING DIVIDEND

DIVIDEND RATE

STATISTICS

FINANCIAL STATEMENT SUMMARY

VALUATION & PROFITABILITY HISTORY

WARNINGS

REPORT TIPS

DISCLAIMER